Everything NICE has said on assessing, diagnosing and managing chronic fatigue syndrome/myalgic encephalomyelitis in an interactive flowchart
Everything NICE has said on preventing, diagnosing and managing stroke and transient ischaemic attack (TIA) in people over 16 in an interactive flowchart
Everything NICE has said on managing hip fracture in adults in an interactive flowchart
Everything NICE has said on the most common primary headache disorders in young people aged 12 years and older and adults in an interactive flowchart
Everything NICE has said on liver and bile duct cancers in an interactive flowchart
Everything NICE has said on gastrointestinal conditions in an interactive flowchart
Everything NICE has said on endocrine, nutritional and metabolic conditions in an interactive flowchart
Everything NICE has said on neurological conditions in an interactive flowchart
This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.
This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.
Everything NICE has said on diagnosing and managing the epilepsies in adults and children in primary and secondary care in an interactive flowchart
Everything NICE has said on diagnosing and managing type 1 diabetes in adults in an interactive flowchart
Everything NICE has said on chronic kidney disease (renal failure) in an interactive flowchart
Everything NICE has said on managing type 2 diabetes in adults in an interactive flowchart
Everything NICE has said on preventing, detecting and managing acute kidney injury in an interactive flowchart
Everything NICE has said on diagnosing and managing type 1 and 2 diabetes in children and young people in an interactive flowchart
Everything NICE has said on diagnosing and treating early and locally advanced breast cancer in an interactive flowchart
Everything NICE has said on assessing, diagnosing, treating and reducing the risk of venous thromboembolism in adults in an interactive flowchart
Everything NICE has said on diagnosing and managing menopause and premature ovarian insufficiency in an interactive flowchart
Everything NICE has said on diverticular disease in an interactive flowchart
Everything NICE has said on thyroid disease in children, young people and adults in an interactive flowchart
NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults
Evidence-based recommendations on rucaparib (Rubraca) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has responded to
Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults
NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over
NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the
NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults
NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma
NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma
NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults
NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults
Evidence-based recommendations on bisphosphonates (alendronic acid; ibandronic acid; risedronate sodium; zoledronic acid) for treating osteoporosis in adults
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to
NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib
Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia (AML) in adults
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults
Evidence-based recommendations on lenalidomide (Revlimid) for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 (CLN2) in children
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for type 2 diabetes in adults
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia
Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up 25 years
Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults
Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung
Evidence-based recommendations on darvadstrocel (Alofisel; stem-cell treatment) for complex perianal fistulas with mildly or non-active luminal Crohn’s disease
Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma (liver cancer) in adults who have had sorafenib
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease